3187 results for «823»
3187 results
Imaging for structural heart disease intervention
19 Feb 2023 – From PCR Tokyo Valves 2023
Consult this session if you want to learn about imaging in structural heart interventions by exploring series of slides on restoration post transcatheter mitral valve repair, diagnostic performance of CT angiography, and AI in aortic complex measurement for TAVI, and more!
Other cardiac interventions
19 Feb 2023 – From PCR Tokyo Valves 2023
Explore innovative approaches to cardiac interventions featured at PCR Tokyo Valves 2023: from performing TricValve implantation in Asian patients to addressing unique cases like transcatheter valve replacement with a novel tricuspid bioprosthesis. Discover how these experts navigated challenging scenarios!
TAVI in patients with heavily calcified aortic root
19 Feb 2023 – From PCR Tokyo Valves 2023
What role does TAVI play in patients' severely calcified roots? Study the use of balloon-expandable devices, assessing the impact of calcification on aortic root rupture, strategies for safe and effective procedures, and when to consider surgical AVR.
Mitral valve implantation and other technology
19 Feb 2023 – From PCR Tokyo Valves 2023
This session offers insight into advanced mitral valve technologies. It covers details of transapical off-pump repair with synthetic chordae, India's success in transcatheter double valve-in-valve, TMVI in failing valves, and more.
Coronary access after TAVI
19 Feb 2023 – From PCR Tokyo Valves 2023
Unlock insights into post-TAVI coronary access. Understand transcatheter aortic valve structure, neo-commissure anatomy, and practical techniques. This session covers topics such as optimising commissure alignment, elective CAG/PCI, ACS, and severe aortic stenosis.
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...
Author
Author
